Evidence of Formation of 1–10 nm Diameter Ice Nanotubes in Double-Walled Carbon Nanotube Capillaries by Yuan Liu (88411)

“…However, the single-walled INTs reported in the literature all possess subnanometer diameters (<1 nm). Herein, based on systematic and large-scale molecular dynamics simulations, we demonstrate the spontaneous freezing transition of liquid water to single-walled INTs with diameters reaching ∼10 nm when confined to capillaries of double-walled carbon nanotubes (DW-CNTs). …”

Evidence of Formation of 1–10 nm Diameter Ice Nanotubes in Double-Walled Carbon Nanotube Capillaries by Yuan Liu (88411)

“…However, the single-walled INTs reported in the literature all possess subnanometer diameters (<1 nm). Herein, based on systematic and large-scale molecular dynamics simulations, we demonstrate the spontaneous freezing transition of liquid water to single-walled INTs with diameters reaching ∼10 nm when confined to capillaries of double-walled carbon nanotubes (DW-CNTs). …”

Evidence of Formation of 1–10 nm Diameter Ice Nanotubes in Double-Walled Carbon Nanotube Capillaries by Yuan Liu (88411)

“…However, the single-walled INTs reported in the literature all possess subnanometer diameters (<1 nm). Herein, based on systematic and large-scale molecular dynamics simulations, we demonstrate the spontaneous freezing transition of liquid water to single-walled INTs with diameters reaching ∼10 nm when confined to capillaries of double-walled carbon nanotubes (DW-CNTs). …”

Evidence of Formation of 1–10 nm Diameter Ice Nanotubes in Double-Walled Carbon Nanotube Capillaries by Yuan Liu (88411)

“…However, the single-walled INTs reported in the literature all possess subnanometer diameters (<1 nm). Herein, based on systematic and large-scale molecular dynamics simulations, we demonstrate the spontaneous freezing transition of liquid water to single-walled INTs with diameters reaching ∼10 nm when confined to capillaries of double-walled carbon nanotubes (DW-CNTs). …”

Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

“…Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. …”

Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

“…Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. …”

The image illustrates the five steps of the experiment. by Deborah Ribeiro Frazão (9188152)

Decreased expression of ATG5 upon the siRNA transfection. by Manisha Naskar (2613763)

K562 cells were treated with 40 nM of miR-214 mimics or a negative mimics control for 24 h, followed by treatment with 50 μM of hemin for 48 h. by Tipparat Penglong (164413)

Atomically Precise Au₄₂ Nanorods with Longitudinal Excitons for an Intense Photothermal Effect by Yingwei Li (701628)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. by Brian D. Carey (6092747)